ClinicalTrials.gg
CompletedNCT06009185Updated Sep 1, 2023

Safety and Efficacy of BIA 5-1058 in PAH

A Phase 2 interventional study of Oral zamicastat in Pulmonary Arterial Hypertension, sponsored by Bial - Portela C S.A.. Completed at 11 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-09-01.

Sponsored by Bial - Portela C S.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Jun 2019, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing zamicastat in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. zamicastat · Pulmonary Arterial Hypertension.

Enrollment
9th of 11
20 · median 44
Started
2019
with 1 other
Phase 2
2 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
11 of 11
Bial - Portela C S.A.

Among the 11 studies testing zamicastat in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 10th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 11 studies testing zamicastat in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About zamicastat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing zamicastat in Pulmonary Arterial Hypertension as a file.
02

Study summary

This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.

Read the detailed description

This is an extension study with Pulmonary Arterial Hypertension (PAH) patients who are under treatment with zamicastat as adjunctive therapy in the study BIA-51058-201.

For patients participating in this extension study, visit "Maintenance Period Visit 3" (MPV3) of the study BIA-51058-201 will also be the first visit (V1) of this extension study (BIA-51058-202). Their treatment with zamicastat will be continued at their individual highest tolerated dose (HTD) for an additional 12 weeks (50 mg, 100 mg, 150 mg or 200 mg).

Further visits will be performed 20 ±3 days (V2, telephone), 41 ±3 days (V3, on-site), 62 ±3 days (V4, telephone) and 83 ±3 days (V5, on-site) after V1. At V5, patients will have the opportunity to continue treatment with zamicastat in a compassionate use program. Patients who will not participate in this compassionate use program will come to the following follow-up visit(s):

  • Follow-up (FU) down-titration (telephone, 14 ±2 days after V5); only applicable in patients taking 150 mg or 200 mg zamicastat
  • FU visit (on-site, 14 ±2 days after last investigational medicinal product (IMP) intake).

The data and safety monitoring board (DSMB) will periodically review the safety data and will issue a recommendation if the study can be continued as planned.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • BIA 5-1058
  • Zamicastat
  • Bial
  • Bial - Portela & Ca, S.A.
  • dopamine ß-hydroxylase (DßH) inhibitor
  • vascular obstruction
  • pulmonary arteries
  • right-heart catheterisation (RHC)
  • idiopathic
  • rare lung disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the extension study, patients had to fulfil all of the following criteria at visit V1 (Day 1, start of the extension study):

  • Have performed MPV3 of the preceding study BIA-51058-201.
  • Able to comprehend and willing to sign an form (ICF).
  • For women: Agreed not to donate ova from the time of informed consent until 30 days after the last IMP intake.
  • For men: Agreed not to donate sperm from the time of informed consent until 90 days after the last IMP intake

Exclusion criteria

Exclusion Criteria:

Patients were to be excluded for any one of the following reasons:

  • Significant non-compliance with the protocol during the preceding study BIA-51058-201 which may have an impact on this extension study.
  • WHO functional class IV as judged by the investigator (reference 1)
  • Two or more consecutive measurements of systolic blood pressure (SBP) \< 95 mmHg or diastolic blood pressure (DBP) \< 50 mmHg measured at visit V1.
  • Uncontrolled diabetes mellitus with ≥ 8.5% within the last three months or at visit V1.
  • Occurrence of an AE during the preceding study which is judged by the investigator as contraindicative to further participation in the extension study.
  • Any disease known to cause pulmonary hypertension other than PAH WHO Group 1.
  • Obstructive lung disease: /Forced Vital Capacity (FEV1/FVC) \< 60% and FEV1 \< 60% of predicted value after bronchodilator administration, as demonstrated and documented by previous spirometry data which, in the opinion of the investigator, represent the clinical state of the patient at the time of visit V1.
  • Restrictive lung disease: Total Lung Capacity (TLC) \< 70% of predicted value, as demonstrated and documented by previous spirometry data which, in the opinion of the investigator, represent the clinical state of the patient at the time of visit V1.
  • History of moderate to severe hepatic impairment ( B and C).
  • Estimated (eGFR) \< 30 mL/min/1.73 m2 (measured at Maintenance period visit 1 (MPV1) of study BIA-51058-201).
  • Use of the following prohibited medication or treatments during study participation: calcium channel blockers (CCBs) if used for the treatment of PAH in vasoreactive patients; drugs containing a catechol group that is metabolised by DβH (e.g. rimiterole, isoprenaline, dopamine, dopexamine or dobutamide) or α- and/or β-blockers.
  • Presence of any other significant or progressive/unstable medical condition that, in the opinion of the investigator, would compromise evaluation of the study treatment or may jeopardise the patient's safety, compliance or adherence to protocol requirements.
  • For women: Pregnancy or breast-feeding. Women of unable or unwilling to undergo pregnancy tests and practice highly effective measures in combination with a barrier method e.g. condom (without spermicidal foam/gel/film/cream/suppository or fat- or oil-containing lubricants), occlusive cap (diaphragm or cervical/vault caps) with spermicidal gel/film/cream /suppository from the time of until 30 days after the last IMP intake. Highly effective methods for women are surgical intervention (e.g. bilateral tubal occlusion), non-hormonal implantable intrauterine device, true sexual abstinence (i.e. when this is in line with the preferred and usual lifestyle of the patient) and vasectomised partner (provided that the partner is the sole sexual partner of the patient and the partner has received medical assessment of the surgical success). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), hormonal contraceptives and withdrawal are not acceptable methods of contraception.
  • For men: Male patients who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved acceptable contraceptive measure from the time of informed consent until 90 days after the last IMP intake. The following methods are acceptable methods of contraception: partner's use of combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); partner's use of progestogen-only hormonal contraception (oral, injectable/implantable, intrauterine hormone-releasing system); partner's use of implantable intrauterine device; surgical sterilisation (for example, vasectomy or bilateral tubal occlusion).
  • Concurrent participation in any other drug study except BIA-51058-201.
  • Vulnerable patients according to Section 1.61 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline for Good Clinical Practice E6.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HTD < 200 mg zamicastat

    Tablets for oral administration under fed conditions. Zamicastat has to be taken in the morning after breakfast. Each patient will continue treatment with the individual highest tolerated dose (HTD) he/she was taking at MPV3 of the study BIA-51058-201 and will take this dose until visit V5.

    Drug: Oral zamicastat

  • Experimental
    HTD 200 mg zamicastat

    Tablets for oral administration under fed conditions containing 100 mg of zamicastat (two tablets of 100 mg). Zamicastat has to be taken in the morning after breakfast. Each patient will continue treatment with the individual highest tolerated dose (HTD) he/she was taking at MPV3 of the study BIA-51058-201 and will take this dose until visit V5.

    Drug: Oral zamicastat

Interventions

  • Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    The number of participants with AEs will be presented. An AE is any untoward medical occurrence in a patient to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease occurring during the course of the study.

    Time frame: Up to 12 weeks

  2. Clinically relevant changes in laboratory parameters: coagulation

    Based on coagulation analysis measurements of prothrombin time test (international normalized ratio). The prothrombin time (PT) test measures how long it takes for a clot to form in a blood sample. The International Normalized Ratio is a type of calculation based on PT test results. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  3. Incidence of clinically relevant changes (abnormalities) in laboratory parameters: biochemistry

    Based on biochemistry analysis measurements (mmol/L) of Sodium, Potassium, Chloride, Calcium, Phosphate . Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  4. Incidence of clinically relevant changes (abnormalities) in laboratory parameters: haematology

    Based on haematology analysis measurement haemoglobin (g/dL). Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  5. Clinically relevant changes in laboratory parameters: urinalysis

    Based on urinalysis analysis measurements of the potential of hydrogen (pH). The pH scale is used to determine the degree of acidity of a substance. The basic pH scale extends from 0 (strong acid) to 7 (neutral, pure water) to 14 (strong caustic). Urine has the widest range of pH compared to other bodily fluids. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  6. Clinically relevant changes in laboratory parameters: arterial blood gas

    Based on arterial blood gas analysis measurements of Fraction of Inspired Oxygen (%). The fraction of inspired oxygen is the concentration or percentage of oxygen in the air that is inhaled by a person. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 12, and from day -1 to week 12

  7. Clinically relevant changes in vital signs: blood pressure

    Systolic and diastolic blood pressure (mmHg) will be measured after the patient has rested for at least 5 minutes in supine position (first measurement) and at least one minute after the first measurement (second measurement). Afterwards, systolic and diastolic blood pressure will be measured again in standing position after the patient has been standing for at least 3 minutes (third measurement). Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  8. Clinically relevant changes in vital signs: pulse rate

    Pulse rate (bpm) will be measured after the patient has rested for at least 5 minutes in supine position (first measurement) and at least one minute after the first measurement (second measurement). Afterwards, vital signs will be measured again in standing position after the patient has been standing for at least 3 minutes (third measurement). Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  9. Clinically relevant changes in electrocardiogram ECG parameter QT interval

    QT interval measures the time (msec) it takes the heart muscle to contract and then recover. Baseline values will be obtained from V1/A1 of study BIA-51058-201. At Baseline of BIA-51058-201 study and week 12, triplicate 12-lead ECG will be recorded before IMP intake as well as 4 and 8 hours after IMP intake.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

  10. Clinically relevant changes in electrocardiogram ECG parameter QRS duration

    The QRS duration measures the time (msec) required for a stimulus to spread through the heart ventricles (ventricular depolarization). Baseline values will be obtained from V1/A1 of study BIA-51058-201. At Baseline of BIA-51058-201 study and week 12, triplicate 12-lead ECG will be recorded before IMP intake as well as 4 and 8 hours after IMP intake.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 6 and week 12

Secondary outcomes

  1. Changes in haemodynamic parameters: pulmonary vascular resistance (PVR)

    Pulmonary vascular resistance (measured in dyn\*s/cm\^5) is determined by right heart catheterization to be performed before IMP intake. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From Baseline to week 12, and from Day -1 to week 12

  2. Changes in haemodynamic parameters: right atrial pressure (RAP)

    Right atrial pressure (RAP), measured in mmHg units, is a robust predictor of the pulmonary hypertension severity. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From Baseline to week 12, and from Day -1 to week 12

  3. Changes in haemodynamic parameters: mean pulmonary artery pressure (mPAP)

    Haemodynamic parameter mean pulmonary artery pressure (mPAP) is measured in mmHg units. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From Baseline to week 12, and from Day -1 to week 12

  4. Changes in haemodynamic parameters: Cardiac index (CI)

    Cardiac index (CI) is a haemodynamic parameter that relates the cardiac output from left ventricle in one minute to body surface area, thus relating heart performance to the size of the individual. The unit of measurement is liters per minute per square meter (L/min/m2). Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From Baseline to week 12, and from Day -1 to week 12

  5. Changes in haemodynamic parameters: mixed venous oxygen saturation (SvO2)

    SvO2 is the percentage (%) of oxygen bound to hemoglobin in blood returning to the right side of the heart. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From Baseline to week 12, and from Day -1 to week 12

  6. Changes in the New York Heart Association / World Health Organization (NYHA/WHO) functional class

    The NYHA/WHO Classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of symptoms at rest and with activity: Class I, patients with pulmonary hypertension but without resulting limitation of physical activity; Class II, patients with pulmonary hypertension resulting in a slight limitation of physical activity; Class III, patients with pulmonary hypertension resulting in marked limitation of physical activity; Class IV: patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

  7. Changes in the 6-minute walk test (6-MWT): Distance Covered

    The 6-MWT is a self-paced test of walking capacity used to assess aerobic capacity and endurance. It plays a key role in evaluation functional exercise capacity, assessing prognosis and evaluating response to treatment across a wide range of respiratory diseases. The distance covered (m) over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

  8. Changes in Biomarker N-terminal pro brain natriuretic peptide (NT-proBNP)

    NT-proBNP levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure, as this marker is typically higher in patients with worse outcome. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

  9. Changes in echocardiogram parameters

    Parameters used include tricuspid regurgitation, right ventricular contractility, pericardial effusion, right atrial end-systolic area, right ventricular end-diastolic area. Tricuspid regurgitation is a type of heart valve disease in which the valve between the two right heart chambers doesn't close properly. As a result, blood leaks backward into the upper right chamber. In was classified as absent, mild, moderate or severe. The right ventricle is the major determinant of functional state and prognosis in PAH. It was measured via tricuspid annular plane systolic excursion (TAPSE). A TAPSE value \< 17 mm is considered to indicate right ventricular dysfunction. A pericardial effusion refers to the accumulation of fluid in the pericardial sac surrounding the heart. It was classified as absent (low risk), traces or present (high risk). Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

  10. Changes in Quality of life 36-item Short Form Health Survey version 2 (SF-36v2)

    The SF-36v2 asks 36 questions (items) to measure the functional health and well-being from the patient's point of view. All 36 questions, except question 2 are used to score the 8 health domains. A total score was calculated for each health domain by taking the sum of the corresponding responses and rescaling it to a range of 0 to 100, where 100 represented the best possible result. Baseline values will be obtained from V1/A1 of study BIA-51058-201.

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

  11. Minimum Plasma Concentration (Cmin) of zamicastat and its metabolites (BIA 5-961 and BIA 5-453)

    The pharmacokinetic (PK) parameter Minimum Plasma Concentration (Cmin) for zamicastat and its metabolites will be derived at the end of the dosing interval. Cmin will be measured in ng/mL units. Blood samples will be obtained prior to IMP intake.

    Time frame: Day -1, week 6 and week 12

  12. Changes in plasma of dopamine ß-hydroxylase (DβH) activity

    The assessment of plasma DβH activity (% inhibition) was performed centrally. Blood sampling for the assessment of plasma DβH activity was to be performed together with the PK blood sampling. Blood samples were to be taken prior to IMP intake. Baseline values will be obtained from V1/A1 of study BIA-51058-201. Day -1 visit

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

  13. Catecholamine (norepinephrine and dopamine) levels urinary pharmacodynamic change from baseline: changes in 24-hour

    24-hour urine collection was to be started on the day before the respective visit. Results for norepinephrine and dopamine are given in nmol per 24 hours (nmol/24hr).

    Time frame: From baseline to week 6 and week 12, and from day -1 to week 12

07

Study locations

11 sites
  • Ordensklinikum Linz Elisabethinen, Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin Fadingerstraße 1
    Linz, 4020, Austria
  • Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Pneumologie Fetscherstraße 74
    Dresden, 01307, Germany
  • ASST di Monza-Ospedale San Gerardo -Dipartimento di Pneumologia via Pergolesi 33
    Monza, 20900, Italy
  • AOU di Roma-Policlinico Umberto I-Unità Dipartimentale Malattie del Circolo Polmonare Viale del Policlinico 155
    Roma, 00161, Italy
  • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital Pulido Valente Consulta Externa de Hipertensão Pulmonar Alameda das Linhas de Torres, 117
    Lisboa, 1769-001, Portugal
  • Hospital Clinic de Barcelona Calle Villarroel, 170
    Barcelona, 08036, Spain
  • Hospital Universitario "12 de Octubre" Avda. de Córdoba, s/n
    Madrid, 28041, Spain
  • Complejo Asistencial Universitario de Salamanca Pº. San Vicente, 58
    Salamanca, 37007, Spain
  • Hospital Universitario Marques de Valdecilla Avenida Valdecilla, 25
    Santander, 39008, Spain
  • Golden Jubilee National Hospital Golden Jubilee National Hospital Agamemnon St, Scottish Pulmonary Vascular Unit Golden Jubilee National Hospital
    Clydebank, G81 4DY, United Kingdom
  • Royal Free Hospital Pond Street
    London, NW3 2QG, United Kingdom
08

References and documents

Publications

  • Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum In: Eur Respir J. 2015 Dec;46(6):1855-6. doi: 10.1183/13993003.51032-2015. PubMed 26318161 ↗
  • Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014 Dec;44(6):1428-46. doi: 10.1183/09031936.00150314. Epub 2014 Oct 30. PubMed 25359355 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Feb 2022, 31 months.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 31 months is close to that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Aug 24, 2023
StartActual
Jun 26, 2019
Primary completionActual
Feb 17, 2022
CompletionActual
Feb 17, 2022
Last update
Sep 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06009185
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Jun 26, 2019
Primary completion
Feb 17, 2022
Completion
Feb 17, 2022
Last update
Sep 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamicastat

Start the discussion